DK1150698T3 - Anvendelser af vaskulær endotelvækstfaktor i behandlingen af erektil dysfunktion - Google Patents

Anvendelser af vaskulær endotelvækstfaktor i behandlingen af erektil dysfunktion

Info

Publication number
DK1150698T3
DK1150698T3 DK00904485T DK00904485T DK1150698T3 DK 1150698 T3 DK1150698 T3 DK 1150698T3 DK 00904485 T DK00904485 T DK 00904485T DK 00904485 T DK00904485 T DK 00904485T DK 1150698 T3 DK1150698 T3 DK 1150698T3
Authority
DK
Denmark
Prior art keywords
subject
growth factor
vascular endothelial
endothelial growth
blood supply
Prior art date
Application number
DK00904485T
Other languages
Danish (da)
English (en)
Inventor
Ridwan Shabsigh
Original Assignee
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Columbia filed Critical Univ Columbia
Application granted granted Critical
Publication of DK1150698T3 publication Critical patent/DK1150698T3/da

Links

Classifications

    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F27—FURNACES; KILNS; OVENS; RETORTS
    • F27D—DETAILS OR ACCESSORIES OF FURNACES, KILNS, OVENS, OR RETORTS, IN SO FAR AS THEY ARE OF KINDS OCCURRING IN MORE THAN ONE KIND OF FURNACE
    • F27D27/00—Stirring devices for molten material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Mechanical Engineering (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DK00904485T 1999-01-21 2000-01-21 Anvendelser af vaskulær endotelvækstfaktor i behandlingen af erektil dysfunktion DK1150698T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/234,591 US6706682B2 (en) 1999-01-21 1999-01-21 Uses of vascular endothelial growth factor in the treatment of erectile dysfunction

Publications (1)

Publication Number Publication Date
DK1150698T3 true DK1150698T3 (da) 2006-01-16

Family

ID=22882011

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00904485T DK1150698T3 (da) 1999-01-21 2000-01-21 Anvendelser af vaskulær endotelvækstfaktor i behandlingen af erektil dysfunktion

Country Status (9)

Country Link
US (2) US6706682B2 (de)
EP (1) EP1150698B1 (de)
JP (1) JP2003501345A (de)
AT (1) ATE303818T1 (de)
AU (1) AU2623700A (de)
CA (1) CA2360058A1 (de)
DE (1) DE60022478T2 (de)
DK (1) DK1150698T3 (de)
WO (1) WO2000043029A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706682B2 (en) * 1999-01-21 2004-03-16 The Trustees Of Columbia University In The City Of New York Uses of vascular endothelial growth factor in the treatment of erectile dysfunction
AU7733800A (en) * 1999-10-01 2001-05-10 Duke University A method of treating erectile dysfunction
AU2001250821A1 (en) * 2000-03-10 2001-09-24 Chiron Corporation Methods and compositions for the treatment and prevention of erectile dysfunction
US7223406B2 (en) 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
EP1365794A2 (de) 2000-07-21 2003-12-03 Lue, Tom Vorbeugung und behandlung von störungen der sexuellen erregbarkeit
WO2007138590A2 (en) * 2006-05-30 2007-12-06 Yossi Gross Implantable pump for drug delivery to treat erectile dysfunction
US8152711B2 (en) * 2007-03-21 2012-04-10 Yossi Gross Implantable peristaltic pump to treat erectile dysfunction
US7818062B2 (en) * 2008-01-31 2010-10-19 Ed Tech Medical Ltd. Peristaltic pump for treatment of erectile dysfunction
US20120183519A1 (en) * 2011-01-13 2012-07-19 Biomet Biologics, Llc Treatment of erectile dysfunction using platelet-rich plasma
WO2016112049A1 (en) 2015-01-06 2016-07-14 Cardiovascular Biotherapeutics, Inc. Angiogenic treatment of ischemic heart disease
EP3259012A4 (de) * 2015-02-16 2018-09-19 CardioVascular BioTherapeutics, Inc. Therapeutische angiogenese zur behandlung erektiler dysfunktionen
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236904A (en) 1989-09-18 1993-08-17 Senetek, Plc Erection-inducing methods and compositions
US5652225A (en) * 1994-10-04 1997-07-29 St. Elizabeth's Medical Center Of Boston, Inc. Methods and products for nucleic acid delivery
US5594032A (en) * 1994-11-10 1997-01-14 Gonzalez-Cadavid; Nestor F. Amelioration of human erectile dysfunction by treatment with iNOS, inducers of iNOS or iNOS cDNA
US5731339A (en) * 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
EP1604674B1 (de) 1998-05-01 2008-11-19 University of Pittsburgh Verwendung von Myoblasten zur Herstellung eines Medikaments zur Behandlung der stressbedingten Harninkontinenz
EP1086494A4 (de) 1998-05-15 2006-09-20 Glaxo Group Ltd Infrarotthermographie
US6706682B2 (en) * 1999-01-21 2004-03-16 The Trustees Of Columbia University In The City Of New York Uses of vascular endothelial growth factor in the treatment of erectile dysfunction
AU7733800A (en) 1999-10-01 2001-05-10 Duke University A method of treating erectile dysfunction

Also Published As

Publication number Publication date
WO2000043029A1 (en) 2000-07-27
EP1150698A1 (de) 2001-11-07
US20040048800A1 (en) 2004-03-11
EP1150698A4 (de) 2003-01-29
JP2003501345A (ja) 2003-01-14
DE60022478D1 (de) 2005-10-13
EP1150698B1 (de) 2005-09-07
ATE303818T1 (de) 2005-09-15
AU2623700A (en) 2000-08-07
US20030124094A1 (en) 2003-07-03
DE60022478T2 (de) 2006-06-22
CA2360058A1 (en) 2000-07-27
US6706682B2 (en) 2004-03-16

Similar Documents

Publication Publication Date Title
DK1150698T3 (da) Anvendelser af vaskulær endotelvækstfaktor i behandlingen af erektil dysfunktion
BR0112361A (pt) Métodos para tratamento de condições oculares mediadas por inflamação
EA200001044A3 (ru) Соединения для лечения женской сексуальной дисфункции
AU4077701A (en) Agent for use in method of treatment
ATE256464T1 (de) Verfahren zur bekämpfung infektiöser krankheiten unter verwendung dikationischer bis-benzimidazole
ATE229335T1 (de) Heterozyklische bizykeln zur behandlung von impotenz
DE60045034D1 (de) Überstände von mesenchymstammzellen zur vorbeugung und behandlung von immunantworten in transplantationen
IS4100A (is) Aðferð við meðhöndlun á ígræðlingi úr málmi fyrirskurðaðgerð
ATE369817T1 (de) Vorrichtung zur abgabe von therapeutischen wirkstoffen
ATE422357T1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
NZ257484A (en) Nucleotides active against tnf-alpha, treatment of viral diseases
AR024380A1 (es) Tienopirimidinas
ATE453402T1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
EP1108426A3 (de) Anwendung von Prostaglandinagonisten zur Behandlung der Erektionstörungen und Impotenz
DE69921008D1 (de) Behandlung von Rückenmarkverletzungenbedingter Impotenz
DE69800859D1 (de) Verwendung von Moxonidin zur Behandlung neuropathischer Schmerzen
ATE320270T1 (de) Zusammensetzungen und methoden zur zielgerichteten abgabe von biologisch aktivenfaktoren
ATE359798T1 (de) Verwendungvon dextransulfat zur behandlung von ibmir
ATE291918T1 (de) Kombinationstherapie zur behandlung von tumoren
WO2004024089A3 (en) Inhibition or activation of adam9 and adam15 for treatment of vascularization-related disease and wound healing
HUP0203486A2 (hu) Véralvadással összefüggő betegségek megelőzése és kezelése
ATE183095T1 (de) Verwendung von prostaglandin-e1 zur behandlung männlicher erektiler impotenz
ATE296631T1 (de) Verwendung von pde5 inhibitoren zur behandlung vorzeitiger ejakulation
DK0900085T3 (da) Behandling af overdreven aggression med olanzapin
UA32241A (uk) Спосіб лікування запалювальних процесів у експериментальних тварин